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Clinical benefits of slowing the progression of renal failure. End-
stage renal disease is a social and economic threat worldwide.
In this context, any medical intervention that may prevent the
progression of chronic kidney disease becomes extremely im-
portant. Improving the cardiovascular status is another major
objective in the management of this population, because cardio-
vascular disease is the leading cause of morbidity and mortality
among dialysis patients. Moreover, this is only the tip of the
iceberg, because many patients die before reaching end-stage
renal disease.
Today, several interventions are available to delay the pro-
gressive loss of renal function and/or prevent the development
of cardiovascular disease, but we are still far from being satis-
fied. These interventions include low protein diets, correction of
calcium-phosphate disorders and anemia, blood pressure and
proteinuria control, and smoking cessation. Other interven-
tions, such as the administration of lipid-lowering agents, are
emerging as particularly promising therapeutic approaches.
Recently, growing attention has been paid to polytherapeutic
approaches to chronic kidney disease, in order to control differ-
ent causal factors involved in progression and reduce them as
much as possible. However, larger prospective, controlled, ran-
domized clinical trials are needed to demonstrate their actual
usefulness.
All the interventions are likely to be more effective if per-
formed as early as possible in the course of the disease, because
it has been widely demonstrated that early and regular nephro-
logic care is associated with decreased morbidity and mortality.
End-stage renal disease (ESRD) is a very significant
and growing social and economic problem worldwide,
and the number of patients requiring renal replacement
therapy (RRT) has increased dramatically and partially
unexpectedly. In 1984, Eggers et al [1] estimated that
117,200 patients would be receiving RRT by 2000. How-
ever, these projections were largely disproved by real-
ity: according to the United States Renal Data System,
a total of 378,862 patients were receiving RRT in 2000
in the United States, with a point prevalence rate of
1367 patients per million population [2]. Similarly, al-
though to a lesser extent, the prevalence of ESRD has
also significantly increased in European countries and has
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been paralleled by increased incidence rates worldwide.
In this perspective, chronic kidney disease (CKD) does
not represent simply a clinical matter, but also a grow-
ing economic and organizational problem, because RRT
consumes a considerable proportion of health care re-
sources. Therefore, any medical intervention that may
prevent the progression of CKD toward ESRD is ex-
tremely important. Preventing cardiovascular disease is
another important objective. It is well known that patients
even with early CKD are at much higher risk of cardiovas-
cular disease in comparison with the general population;
cardiovascular disease accounts for 30% of hospitaliza-
tions and for more than 50% of deaths in dialysis patients.
The prevalence of cardiovascular disease is already high
at the beginning of RRT [3, 4], which suggests that the
pathogenetic mechanisms have been operating well be-
fore. This is also witnessed by the fact that in patients
with CKD in the conservative phase at all stages, the oc-
currence of death is far more common than the need for
dialysis [5], which confirms the high burden of cardio-
vascular disease in this population. For this reason, the
management of CKD in the conservative phase should
also comprise all available therapeutic options aimed at
preventing or reducing the development of cardiac ab-
normalities and vascular disease.
DIET MANAGEMENT
Once considered one of the most important steps in
the treatment of CKD, the role of dietary protein re-
striction in slowing down the progression of CKD has
been largely reappraised in recent years. In an Italian
multicenter study comparing a low protein diet (0.6 g/kg
body weight/day) with a “normal” controlled protein diet
(1.0 g/kg body weight/day), the favorable effect of a low
protein diet on cumulative renal survival was only of bor-
derline significance (P < 0.06) [6]. Similarly, the Mod-
ification of Diet in Renal Disease (MDRD) study [7]
was unable to demonstrate a significant effect of low pro-
tein diets in slowing down the rate of CKD progression.
According to an estimate we performed some years ago
starting with the results from the MDRD study, the adher-
ence to a low protein diet for nearly 9 years could delay
the beginning of RRT of no more than 1 year (Fig. 1)
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Fig. 1. The effect of the low protein diet in the MDRD Study A: Time
to ESRD [8].
[8]. However, we have to balance this with the fact that
these diets are very demanding on patients and their fam-
ilies and could expose to the risk of malnutrition. Dietary
counseling remains a fundamental step in the manage-
ment of CKD patients, who have to be taught to assume a
hyposodic diet with controlled protein and phosphate in-
take and adequate caloric content, especially in the more
advanced phases of CKD (when the risk of malnutrition
is higher).
BLOOD PRESSURE AND PROTEINURIA
CONTROL
Not only is hypertension an important presenting fea-
ture of CKD but, together with proteinuria, it is a major
factor contributing to its progression. As a consequence,
effective anti-hypertensive therapy is the cornerstone of
treatment in CKD patients, excepting the possible treat-
ment of primary disease.
Over the last decade, a number of trials have been per-
formed to assess the degree of blood pressure (BP) re-
duction needed to achieve renoprotection. In the MDRD
study, aside from randomization to two different dietary
protein intakes, patients were also randomized to a usual
BP control or to a stricter BP control [7]. In study A
(baseline GFR 25–55 mL/min), the mean decline in GFR
was faster in the first 4 months of follow-up and slower
thereafter in the strictthan in the usual BP group, while in
patients with more advanced CKD, the decline of GFR
was linear and did not differ significantly between the two
BP groups. The patients with higher levels of baseline pro-
teinuria received greater benefits from being assigned to
a low BP target. According to the estimate mentioned
previously [8], a stricter control of BP could delay the
time to ESRD by 1.24 years over a period of 9.4 years
compared with the usual BP target of those years. Very
recently, Sarnak et al [9] published the results of the long-
term follow-up of this study. After a median of 5.9 years,
ESRD developed in 62% of the participants in the low
target BP group and in 70% of the patients in the usual
BP group, indicating a significant reduced risk for kid-
ney failure with the low BP target (after controlling for
covariates, hazard ratioof 0.68; confidence interval, 0.57–
0.82). This effect was similar during follow-up, without
any difference between intervals during or after the ran-
domized trial. As expected, the risk reduction tended to
be larger in patients with more severe proteinuria.
The African American Study of Kidney Disease and
Hypertension study [10] was designed afterwards to as-
sess the impact of two BP goals (102–107 mm Hg and
≤92 mm Hg, respectively) and three different drug reg-
imens (ramipril, amlodipine, and metoprolole) on the
progression of hypertensive nephrosclerosis in African
Americans. However, in this specific population, a lower
BP control did not result in a better outcome compared
with the usual control. These negative findings could be
partially explained by the fact that the selected patients
had only mild proteinuria or that they were predomi-
nately African Americans.
Given the clear relationship between urinary protein
excretion and BP levels, any anti-hypertensive therapy
has the potential to decrease proteinuria and CKD pro-
gression. However, some agents are probably capable
of reducing CKD progression, because they also halt
other pathogenetic mechanisms involved in glomerular
and tubular-interstitial renal damage; this is particularly
true for drugs blocking the renin-angiotensin system, as
demonstrated by a number of clinical trials [11–13]. These
findings were confirmed by a meta-analysis of 11 ran-
domized trials comparing the efficacy of antihypertensive
regimens including those in patients with nondiabetic re-
nal disease. After adjustment for changes in BP, the rel-
ative risk in the angiotensin-converting enzyme (ACE)
inhibitor group compared with standard antihypertensive
therapy was 0.69 for ESRD and 0.70 for the combined
end point of the doubling of baseline serum creatinine or
ESRD [14].
In patients with type 2 diabetic nephropathy, the Re-
duction of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan study [15] and the Irbesartan Dia-
betic Nephropathy Trial [16] have shown that angiotensin
receptor blockers (ARBs) are able to slow down the pro-
gression of nephropathy at least partly independently of
their capacity to lower BP.
In the majority of these studies, systolic BP and di-
astolic BP values achieved with the experimental treat-
ment were lower than those obtained during standard
anti-hypertensive therapy. This has raised the contro-
versy whether these drugs are really superior to other
antihypertensive agents when recommended BP values
are achieved. Very recently, Ruggenenti et al [17] pub-
lished the results of the REIN-2 study. This was a multi-
center, randomized, controlled trial of 338 patients with
nondiabetic proteinuric nephropathies receiving ACE in-
hibitors, who were randomized to conventional (diastolic
BP < 90 mm Hg) or intensive (systolic BP/diastolic BP
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<130/80 mm Hg) BP control. Over a median follow-up of
19 months, a similar percentage of patients progressed to
ESRD (nearly 20%) in the two groups, suggesting no ad-
ditional benefit from intensive BP control when patients
were already treated with an ACE inhibitor, at least as far
as renoprotection was concerned. Indeed, BP reduction
is, in any case, of paramount importance to reduce the
burden of cardiovascular disease in this population.
It has been hypothesized that complete inhibition of
the renin-angiotensin system by dual blockage with ACE
inhibitors and ARBs would be most beneficial in the man-
agement of progressive CKD than either agent alone.
The COOPERATE study [18] seems to confirm that com-
bination treatment safely retards progression compared
with monotherapy. After 3 years of follow-up, 11% of
the patients on combination treatment reached the com-
bined primary end point of the doubling of serum cre-
atinine from baseline or ESRD compared with 23% of
those treated with the two agents alone. These obser-
vations are in line with the results of a meta-analysis,
which was preliminarily presented at the 2004 American
Society Annual Meeting [19]. The authors found a signif-
icantly higher antiproteinuric effect of combination ther-
apy compared with ACE inhibitors or ARBs alone (mean
proteinuria reduction of 64.6% vs. 37.7%, respectively).
However, further studies are still awaited to better con-
firm this therapeutic option.
USE OF STATINS
On the ground of experimental observations in animal
models and human renal biopsies, dislipidemia has been
suggested as one of the pathogenetic factors involved in
CKD progression. This hypothesis seems to be in line
with the results of some clinical studies [20, 21]. In this
perspective, the administration of statins could be par-
ticularly useful in CKD patients, considering that these
agents could reduce the fibrogenic and inflammatory re-
sponse often observed in many nephropathies. Confirma-
tion of this comes from a number of experimental studies
that suggest a direct action of statins in halting extra-
cellular matrix accumulation, overexpression of connec-
tive growth factors [22], and tubular-interstitial fibrosis
[23].From the clinical point of view, a number of small
studies, the results of which have been collected in a
meta-analysis [24], seem to suggest an anti-proteinuric
effect of statins. Furthermore, these agents may be able
to slow down the rate of CKD progression [24]. More
recently, Bianchi et al [25] performed a prospective, ran-
domized trial in 56 CKD patients who had received an
ACE inhibitor or an ARB for 1 year and were then ran-
domized to receive or not receive atorvastatin while still
being administered their previous therapy. Adding the
statin caused a significant reduction in proteinuria levels
(from 2.2 ± 0.1 g/day to 1.2 ± 1.0 g/day), which remained
substantially unmodified in the group of patients not re-
ceiving atorvastatine (from 2.0 ± 0.1 g/day to 1.8 ± 1.0
g/day). In addition, creatinine clearance remained stable
in those treated with the statin (from 51 ± 1.8 mL/min to
49.8 ± 1.7 mL/min), whereas it progressively decreased
in the control group (from 50 ± 1.9 mL/min to 44.2 ± 1.6
mL/min). Larger studies are awaited in this field.
Given the high cardiovascular risk of this population,
treatment with statins could also have a role in preventing
or reducing the burden of cardiovascular disease. Unfor-
tunately, no prospective, randomized studies have been
performed so far in patients with CKD in the conserva-
tive phase. However, secondary analyses of large trials
performed on both primary and secondary prevention in
more heterogeneous populations seem to suggest a posi-
tive effect of statins in CKD patients also [26, 27].
CORRECTION OF ANEMIA
Anemia is highly prevalent in CKD patients. This com-
plication is associated not only with a worse quality of
life, but also with increased prevalence of cardiovascular
disease and higher rates of hospitalization. Hemoglobin
levels start to decrease quite early during the course of
chronic nephropathies, well before the start of RRT [28].
It is therefore expected that anemia correction, partic-
ularly if started early in the conservative phase, could
improve the cardiovascular outcome of this population.
Small studies have shown that treatment of anemia with
erythropoietin is able to reverse some of the functional
and morphologic cardiac changes seen in CKD [29]. How-
ever, large, randomized, controlled studies [30–32], which
were mainly performed in patients already on RRT (and
thus with more advanced cardiovascular disease), were
unable to demonstrate a major effect of a complete cor-
rection of anemia in reducing the risk for hard end points,
such as death or major cardiovascular events. Given these
considerations, current European Best Practice Guide-
lines for the management and treatment of anemia in
CKD patients suggest to achieve a hemoglobin target of
≥11 g/dL [33]. Higher values could be considered for in-
dividual patients, taking gender, age, ethnicity, activity,
and comorbid conditions into account.
Starting from the experimental observation that hy-
poxia could worse kidney damage, it has been hypothe-
sized that anemia correction may have favorable effects
in slowing down the progression of CKD. However, ev-
idence on this issue is still very limited. Preliminary ob-
servations were obtained in small and/or retrospective
studies [34, 35]. More recently, secondary analyses of two
trials aimed at testing the effect of anemia normalization
on mortality were not able to demonstrate any effect of
the progression of CKD [31, 32]. However, in one of the
two studies [31], the analysis was performed only in a
limited number of patients who were in the conservative
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phase (72 out of 416). Moreover, diastolic BP values at
the end of follow-up were higher in patients assigned to
the higher hemoglobin target, possibly confounding the
analysis. The other study [32], which was performed on
155 CKD patients not on RTT, suffered from the limi-
tation that only a few patients reached the hemoglobin
target, which led to an insufficient split of hemoglobin val-
ues between the two groups and thus reduced statistical
power. More recently, a Greek randomized study found
a significant reduction in the risk of developing ESRD
or death in those who were put to a hemoglobin target
higher than 13 g/dL compared with the control group
(treatment with erythropoietin only in the case of a drop
of hemoglobin below 9 g/dL) [36]. However, the particu-
lar high number of patients reaching the end point during
a median follow-up of only 22.5 months imposes caution
in the interpretation of these results.
CORRECTION OF CALCIUM-PHOSPHATE
DISORDERS
Disturbances of calcium-phosphate metabolism play a
key role in CKD, making an important contribution to
the development of osteodistrophy. In the past few years,
evidence has increased about the fact that elevated lev-
els of serum phosphorus and subsequent secondary hy-
perparathyroidism not only cause bone disease, but also
significantly contribute to the high morbidity and mortal-
ity of CKD patients. In a study of 6047 patients receiving
hemodialysis for at least 1 year, higher levels of phos-
phatemia were associated with increased risk of death,
even after adjustment for pre-existing medical conditions,
delivered dose of dialysis, and estimates of nutritional
status and noncompliance [37]. More recently, the same
authors analyzed data from 40,538 hemodialysis patients
and confirmed an increased relative risk of death in those
with serum phosphorus concentrations >5.0 mg/dL [38].
Higher adjusted serum calcium concentrations were also
associated with an increased risk of death.
Even if the exact pathogenetic mechanisms explaining
these associations are still unknown, it is now quite clear
that calcium-phosphate disorders contribute to vascular
and tissue calcifications, especially those involving coro-
nary arteries, cardiac valves, and myocardial tissue. In this
context, the definition of hyperphosphoremia as a “silent
killer” seems to be appropriate. Given these consider-
ations, adequate control of phosphate and parathyroid
hormone (PTH) levels is extremely important in CKD
patients. Unfortunately, the therapeutic tools now avail-
able are still unsatisfactory and laden by a number of side
effects. This is testified by the low percentage of patients
that, according to the results of the DOOPSstudy, reach
target values of calcium, phosphate, and PTH recom-
mended by current guidelines. We hope that calcimimet-
ics and new vitamin D analogues could be of better help.
SMOKING CESSATION
The potential mechanisms of smoking-related nephro-
toxicity are many, including both acute and chronic path-
ways. Smoking patients with type 1 or type 2 diabetes
are at higher risk of developing microalbuminuria fol-
lowed byproteinuria (i.e., overt diabetic nephropathy).
Moreover, they have an accelerated progression of di-
abetic nephropathy toward ESRD in comparison with
nonsmoking diabetics [39]. The adverse effects of smok-
ing on CKD progression have been also shown in non-
diabetic renal diseases [40]. These data, taken together
with the increased cardiovascular risk related to smok-
ing, suggest that cessation of smoking has to be taken
into consideration by physicians as a primary goal in the
management of CKD patients.
THE IMPORTANCE OF EARLY REFERRAL TO
NEPHROLOGISTS
All the interventions available today in the conserva-
tive phase of CKD are likely to be more effective if per-
formed as early as possible in the course of the disease.
The detrimental effects of late referral have been widely
highlighted, both in terms of higher morbidity and higher
mortality. An early referral to nephrologic care, in addi-
tion to its beneficial effects for patient health, could also
lead to significant advantages in terms of cost savings for
society [41].
Despite this evidence, late referral is a widespread
problem in all countries, and no decreases in its rate have
been registered in recent years. However, a hypothetical
increase in the referral rate to nephrologists would not be
free from organizational problems. Given the high and in-
creasing prevalence of CKD patients, the evaluation of
the cost-effectiveness of screening programs of groups
at higher risk of developing progressive CKD (e.g., el-
derly patients with diabetes or hypertension) and the de-
velopment of new models of health care delivery, the
involvement of nephrologists and other physicians and
non-physicians in an integrated way will be an inevitable
strategy for the future.
Reprint requests to Prof Dr. Francesco Locatelli, Department of
Nephrology and Dialysis, A. Manzoni Hospital, Via dell’Eremo 9/11,
23900 Lecco, Italy.
E-mail: nefrologia@ospedale.lecco.it
REFERENCES
1. EGGERS PW, CONNERTON R, MCMULLAN M: The Medicare experi-
ence with end-stage renal disease: Trends in incidence, prevalence,
and survival. Health Care Fin Rev 5:69–88, 1984
2. UNITED STATES RENAL DATA SYSTEM: USRDS 2004 Annual Data
Report: Atlas of End-Stage Renal Disease in the United States,
Bethesda, MD, National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases, 2004
3. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of car-
diovascular disease in chronic renal disease. Am J Kidney Dis 32
(Suppl 3):112–119, 1998
S-156 Locatelli et al: Benefits of slowing renal failure
4. LOCATELLI F, MARCELLI D, CONTE F, et al: Patient selection affects
end-stage renal disease outcome comparisons. Kidney Int 57(Suppl
74):S94–S99, 2000
5. KEITH DS, NICHOLS GA, GULLION CM, et al: Longitudinal follow-up
and outcomes among a population with chronic kidney disease in
a large managed care organization. Arch Intern Med 164:659–663,
2004
6. LOCATELLI F, ALBERTI D, GRAZIANI G, et al: Prospective, ran-
domised, multicentre trial of effect of protein restriction on pro-
gression of chronic renal insufficiency. Northern Italian Cooperative
Study Group. Lancet 337:1299–1304, 1991
7. KLAHR S, LEVEY AS, BECK GJ, et al: AND THE MODIfiCATION OF DIET IN
RENAL DISEASE STUDY GROUP: The effects of dietary protein restric-
tion and blood pressure control on the progression of renal disease.
N Engl J Med 330:877–884, 1994
8. LOCATELLI F, DEL VECCHIO L: How long can dialysis be postponed
by low protein diet and ACE inhibitors? Nephrol Dial Transplant
14:1360–1364, 1999
9. SARNAK MJ, GREENE T, WANG X, et al: The effect of a lower target
blood pressure on the progression of kidney disease: Long-term
follow-up of the modification of diet in renal disease study. Ann
Intern Med 142:342–351, 2005
10. WRIGHT JT, JR., BAKRIS G, GREENE T, et al: African American Study
of Kidney Disease and Hypertension Study Group: Effect of blood
pressure lowering and antihypertensive drug class on progression
of hypertensive kidney disease: results from the AASK trial. JAMA
288:2421–2431, 2002
11. LEWIS EJ, HUNSICKER LG, RAYMOND PB, ROHDE RD: The effect of
angiotensin-converting-enzyme inhibition on diabetic nephropathy.
The Collaborative Study Group. N Engl J Med 329:1456–1462, 1993
12. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin-
converting-enzyme inhibitor benazepril on the progression of
chronic renal insufficiency. The Angiotensin-Converting-Enzyme
Inhibition in Progressive Renal Insufficiency Study Group. N Engl
J Med 334:939–945, 1996
13. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI
IN NEFROLOGIA): Randomised placebo-controlled trial of effect of
ramipril on decline in glomerular filtration rate and risk of termi-
nal renal failure in proteinuric, non-diabetic nephropathy. Lancet
349:1857–1863, 1997
14. JAFAR TH, SCHMID CH, LANDA M, et al: Angiotensin-converting
enzyme inhibitors and progression of nondiabetic renal disease. A
meta-analysis of patient-level data. Ann Intern Med 135:73–87, 2001
15. BRENNER BM, COOPER ME, DE ZEEUW D, et al: RENAAL Study
Investigators: Effects of losartan on renal and cardiovascular out-
comes in patients with type 2 diabetes and nephropathy. N Engl J
Med 345:861–869, 2001
16. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: COLLABORATIVE STUDY
GROUP: Reno-protective effect of the angiotensin-receptor antago-
nist irbesartan in patients with nephropathy due to type 2 diabetes.
N Engl J Med 345:851–860, 2001
17. RUGGENENTI P, PERNA A, LORIGA G, et al: REIN-2 Study Group:
Blood-pressure control for renoprotection in patients with non-
diabetic chronic renal disease (REIN-2): Multicentre, randomised
controlled trial. Lancet 365:939–946, 2005
18. NAKAO N, YOSHIMURA A, MORITA H, et al: Combination treatment
of angiotensin-II receptor blocker and angiotensin-converting-
enzyme inhibitor in non-diabetic renal disease (COOPERATE):
A randomised controlled trial. Lancet 361:117–124, 2003
19. OWDA AK, et al: J Am Soc Nephrol 15:119A, 2004
20. SAMUELSSON O, MULEC H, KNIGHT-GIBSON C, et al: Lipoprotein ab-
normalities are associated with increased rate of progression of hu-
man chronic renal insufficiency. Nephrol Dial Transplant 12:1908–
1915, 1997
21. MUNTNER P, CORESH J, SMITH JC, et al: Plasma lipids and risk of de-
veloping renal dysfunction: The atherosclerosis risk in communities
study. Kidney Int 58:293–301, 2000
22. SONG Y, LI C, CAI L: Fluvastatin prevents nephropathy likely
through suppression of connective tissue growth factor-mediated
extracellular matrix accumulation. Exp Mol Pathol 76:66–75, 2004
23. LI C, YANG CW, PARK JH, et al: Pravastatin treatment attenu-
ates interstitial inflammation and fibrosis in a rat model of chronic
cyclosporine-induced nephropathy. Am J Physiol Renal Physiol
286:F46–F57, 2004
24. FRIED LF, ORCHARD TJ, KASISKE BL: Effect of lipid reduction on the
progression of renal disease: A meta-analysis. Kidney Int 59:260–
269, 2001
25. BIANCHI S, BIGAZZI R, CAIAZZA A, CAMPESE VM: A controlled,
prospective study of the effects of atorvastatin on proteinuria and
progression of kidney disease. Am J Kidney Dis 41:565–570, 2003
26. HEART PROTECTION STUDY COLLABORATIVE GROUP:. Lancet 360:7–
22, 2002
27. TONELLI M, ISLES C, CURHAN GC, et al: Effect of pravastatin on
cardiovascular events in people with chronic kidney disease. Circu-
lation 110:1557–1563, 2004
28. ASTOR BC, MUNTNER P, LEVIN A, et al: Association of kidney func-
tion with anemia: The Third National Health and Nutrition Exam-
ination Survey (1988–1994). Arch Int Med 162:1401–1408, 2002
29. HAYASHI T, SUZUKI A, SHOJI T, et al: Cardiovascular effect of normal-
izing the hematocrit level during erythropoietin therapy in predial-
ysis patients with chronic renal failure. Am J Kidney Dis 35:250–256,
2000
30. BESARAB A, BOLTON WK, BROWNE JK, et al: The effects of normal
as compared with low hematocrit values in patients with cardiac
disease who are receiving hemodialysis and epoetin. New Engl J
Med 339:584–590, 1998
31. FURULAND H, LINDE T, AHLMEN J, et al: A randomized controlled
trial of haemoglobin normalization with epoetin alfa in pre-dialysis
and dialysis patients. Nephrol Dial Transplant 18:353–361, 2003
32. ROGER SD, MCMAHON LP, CLARKSON A, et al: Effects of early and
late intervention with epoetin alpha on left ventricular mass among
patients with chronic kidney disease (stage 3 or 4): Results of a
randomized clinical trial. J Am Soc Nephrol 15:148–156, 2004
33. LOCATELLI F, ALJAMA P, BARANY P, et al: Revised European Best
Practice Guidelines for the Management of Anaemia in Patients
with Chronic Renal Failure. Nephrol Dial Transplant 19:1029–1346,
2004
34. KURIYAMA S, TOMONARI H, YOSHIDA H, et al: Reversal of anemia
by erythropoietin therapy retards the progression of chronic re-
nal failure, especially in nondiabetic patients. Nephron 77:176–185,
1997
35. JUNGERS P, CHOUKROUN G, OUALIM Z, et al: Beneficial influence of
recombinant human erythropoietin therapy on the rate of progres-
sion of chronic renal failure in predialysis patients. Nephrol Dial
Transplant 16:307–312, 2001
36. GOUVA C, NIKOLOPOULOS P, IOANNIDIS JPA, et al: Treating anemia
early in renal failure patients slows the decline of renal function: A
randomised controlled trial. Kidney Int 66:753–760, 2004
37. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, et al: Association of
serum phosphorus and calcium × phosphate product with mortality
risk in chronic hemodialysis patients: A national study. Am J Kidney
Dis 31:607–617, 1998
38. BLOCK GA, KLASSEN PS, LAZARUS JM, et al: Mineral metabolism,
mortality, and morbidity in maintenance hemodialysis. J Am Soc
Nephrol 15:2208–2218, 2004
39. BIESENBACH G, JANKO O, ZAZGORNIK J: Similar rate of progression in
the predialysis phase in type I and type II diabetes mellitus. Nephrol
Dial Transplant 9:1097–1102, 1994
40. REGALADO M, YANG S, WESSON DE: Cigarette smoking is associated
with augmented progression of renal insufficiency in severe essential
hypertension. Am J Kidney Dis 35:687–694, 2000
41. MCLAUGHLIN K, MANNS B, CULLETON B, et al: An economic evalu-
ation of early versus late referral of patients with progressive renal
insufficiency. Am J Kidney Dis 38:1122–1128, 2001
